Quick Answer
NovaBridge Biosciences reported Cash and Equivalents of $68.26 million for fiscal year 2024.
NovaBridge Biosciences Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $68.26M | -76.6% |
| 2023 | $291.51M | -15.0% |
| 2022 | $342.92M | -90.3% |
| 2021 | $3.52B | -26.0% |
| 2020 | $4.76B | +318.4% |
| 2019 | $1.14B | -28.4% |
| 2018 | $1.59B | — |
- NovaBridge Biosciences showed a decrease of -76.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2024 period, NovaBridge Biosciences’s cash and equivalents has declined by 95.7% (from $1.59 billion to $68.26 million).
- The most recent figure is from NovaBridge Biosciences’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: